Hugel has been developing and introducing new technologies based on botulinum toxin manufacturing technology in cooperation with the best researchers at home and abroad, mainly in the field of cosmetic surgery and therapeutics.
Hugel creates new value through continuous management innovation and is evolving into a truly global biopharmaceutical company.VIEW MORE
Hugel has been developing into a truly global biopharmaceutical company by constantly creating new value, and we will continue to lead the way for Korea to become a powerhouse in the bio sector.
Hugel resubmits BLA for its botulinum t..
Hugel Appoints Co-CEOs...Strengthens Bu..
Hugel Achieves Record-High Revenue and O..
Hugel Reports 1Q23 Revenue of KRW64.4bn..
Hugel Appointed Suk-yong Cha as Executiv..
Hugel Nominates Suk-yong Cha as Non-Exe..
We will provide maximum investment value through securing future growth engines.